RankAlpha logo
Back to Rankings

TGTX

TG TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
BRIUMVI is still showing strong commercial momentum, Q1 revenue and guidance were raised, and ENHANCE removes a key convenience barrier if the supplemental filing succeeds. At roughly $37.94 versus a median street target of $44.43, the stock still has room to rerate if growth and label expansion both persist.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.9.
What can break
BRIUMVI's growth remains dependent on sustained prescription demand, payer coverage, infusion-center execution, and manufacturing/supply reliability.
Momentum
80
Value
52
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $44.50 · Bull $57.00 · Bear $28.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $44.43
Why
Momentum80 · Δ7d -7.9
Value52 · Δ7d +0.3
Sentiment72 · Δ7d +9.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
80
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.9
Δ21d
-7.8
Value
52
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.6
Sentiment
72
33% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+25.4
Why this grade

Composite grade A. Momentum 80.4 / Value 52.0 / Sentiment 72.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.73B
Beta
1.85
Shares Out
158.76M
P/E (TTM)
10.8
P/S (TTM)
8.92
P/FCF (TTM) · Derived
-83.00
Rev YoY
+92.8%
EPS YoY
+9957.8%
Gross Margin
+85.3%
Op Margin
+19.3%
Net Debt
-$66.57M
Current Ratio
3.82
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology